Certara (NASDAQ:CERT) Shares Down 6.6% - Here's Why

Key Points

• Certara shares fell 6.6% to about $9.40 during mid-day trading, with volume roughly 59% below the average daily level.
• Analyst sentiment remains mixed but leans neutral: the stock has an average “Hold” rating and a consensus price target of $8.45, below its trading price.
• Certara’s latest quarterly results missed expectations, with EPS of $0.08 versus $0.09 expected and revenue of $93.27 million versus $98.09 million anticipated; revenue declined 10.8% year over year.

Certara, Inc. (NASDAQ:CERT - Get Free Report) shares fell 6.6% during mid-day trading on Tuesday. The company traded as low as $9.44 and last traded at $9.4030. 1,421,391 shares changed hands during mid-day trading, a decline of 59% from the average daily volume of 3,494,374 shares. The stock had previously closed at $10.07.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the company. UBS Group reiterated a "neutral" rating and issued a $10.00 price objective on shares of Certara in a report on Wednesday, September 30th. Barclays upped their price objective on shares of Certara from $6.50 to $7.50 and gave the stock an "equal weight" rating in a report on Wednesday, August 5th. Finally, Weiss Ratings upgraded Certara from a "sell (e+)" rating to a "sell (d)" rating in a research note on Wednesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Hold" and a consensus target price of $8.45.

Certara Stock Down 7.8%

The firm has a market cap of $1.42 billion, a PE ratio of -20.66 and a beta of 1.42. The company has a current ratio of 2.55, a quick ratio of 2.55 and a debt-to-equity ratio of 0.30. The firm has a 50 day moving average price of $8.32 and a 200-day moving average price of $6.78.

Certara (NASDAQ:CERT - Get Free Report) last issued its quarterly earnings results on Tuesday, August 4th. The company reported $0.08 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.09 by ($0.01). Certara had a positive return on equity of 3.86% and a negative net margin of 16.75%.The firm had revenue of $93.27 million during the quarter, compared to analysts' expectations of $98.09 million. During the same quarter in the prior year, the firm earned $0.07 EPS. The firm's revenue was down 10.8% compared to the same quarter last year. Research analysts forecast that Certara, Inc. will post 0.22 EPS for the current fiscal year.

Institutional Trading of Certara

Several institutional investors and hedge funds have recently bought and sold shares of CERT. Integrated Wealth Concepts LLC acquired a new position in Certara in the 2nd quarter valued at about $39,000. NorthRock Partners LLC acquired a new position in Certara during the 2nd quarter worth approximately $68,000. State of Wyoming acquired a new stake in shares of Certara in the 2nd quarter valued at approximately $72,000. Perigon Wealth Management LLC acquired a new position in Certara during the second quarter worth $80,000. Finally, Quantbot Technologies LP purchased a new stake in shares of Certara during the 2nd quarter worth $82,000. Hedge funds and other institutional investors own 73.96% of the company's stock.

Certara Company Profile

Certara, Inc NASDAQ: CERT provides software and technology-enabled services for the biopharmaceutical industry. The company helps drug developers use regulatory science, data analysis, and modeling and simulation to support decisions throughout the research, development, and commercialization lifecycle.

Its offerings include software for pharmacokinetic and pharmacodynamic modeling, clinical trial design, patient and disease modeling, regulatory submissions, and real-world data analysis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.